Sideroblastic anemia historical perspective

Revision as of 16:52, 7 September 2018 by Khurram Afzal (talk | contribs)
Jump to navigation Jump to search

Sideroblastic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sideroblastic Anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sideroblastic anemia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sideroblastic anemia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sideroblastic anemia historical perspective

CDC on Sideroblastic anemia historical perspective

Sideroblastic anemia historical perspective in the news

Blogs on Sideroblastic anemia historical perspective

Directions to Hospitals Treating Sideroblastic anemia

Risk calculators and risk factors for Sideroblastic anemia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nazia Fuad M.D.

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

X-linked sideroblastic anemia was first described by Cooley (1945), a Detroit pediatrician-hematologist. He considered possible X-linkage in a family in which 19 males in 5 generations were affected, with transmission through unaffected females. In 1946 Rundles and Falls reported 2 families. Slightly enlarged spleens and minor red cell abnormalities without anemia were observed in female carriers. Pyridoxine responsiveness was observed in at least 2 affected members of Rundles and Falls' family In 1961 Byrd and Cooper named the disorder as hereditary iron-loading anemia. In 1983 Peto et al concentrated on iron overload in mild sideroblastic anemia after the death from cardiac siderosis of a middle-aged woman with a very mild form of familial sideroblastic anemia. Cotter et al. (1995) described a previously healthy 81-year-old woman with microcytic sideroblastic anemia. The diagnosis of the X-linked congenital sideroblastic anemia resulted in successful treatment with pyridoxine. She was diagnosed to be heterozygous for a point mutation of the ALAS2 gene. Aivado (2006) reported a family in which a mother and her 2 daughters had sideroblastic anemia that was unresponsive to pyridoxine. It was confirmed by genetic analysis. The disorder was variable in severity and X-chromosome inactivation studies were done. In 1971 Hines found decreased levels of pyridoxal phosphokinase in red cells and livers of patients with pyridoxine-dependent refractory sideroblastic anemia. In 1973A Oki found deficiency of delta-aminolevulinic acid synthetase in the red cells of patients with sideroblastic anemia. In 2001 Levi discovered that iron accumulates in the mitochondria of red cell precursors.

Historical Perspective

  • X-linked sideroblastic anemia was first described by Cooley (1945), a Detroit pediatrician-hematologist.
  • He considered possible X-linkage in a family in which 19 males in 5 generations were affected, with transmission through unaffected females.
  • In 1946 Rundles and Falls reported 2 families.
  • Slightly enlarged spleens and minor red cell abnormalities without anemia were observed in female carriers.
  • Pyridoxine responsiveness was observed in at least 2 affected members of Rundles and Falls' family
  • In 1961 Byrd and Cooper named the disorder as hereditary iron-loading anemia
  • In 1983 Peto et al concentrated on iron overload in mild sideroblastic anemia after the death from cardiac siderosis of a middle-aged woman with a very mild form of familial sideroblastic anemia.
  • Cotter Pd. (1995) described a previously healthy 81-year-old woman with microcytic sideroblastic anemia.
  • The diagnosis of the X-linked congenital sideroblastic anemia resulted in successful treatment with pyridoxine.
  • She was diagnosed to be heterozygous for a point mutation of the ALAS2 gene.
  • Aivado (2006) reported a family in which a mother and her 2 daughters had sideroblastic anemia that was unresponsive to pyridoxine.
  • It was confirmed by genetic analysis.
  • The disorder was variable in severity and X-chromosome inactivation studies were done.
  • In 1971 Hines found decreased levels of pyridoxal phosphokinase in red cells and livers of patients with pyridoxine-dependent refractory sideroblastic anemia.
  • In 1973A oki found deficiency of delta-aminolevulinic acid synthetase in the red cells of patients with sideroblastic anemia.
  • Cotter in 1994 identified mutation in the ALAS2 gene.
  • In 2001 Levi discovered that iron accumulates in the mitochondria.[1]

References

  1. Aivado M, Gattermann N, Rong A, Giagounidis AA, Prall WC, Czibere A, Hildebrandt B, Haas R, Bottomley SS (2006). "X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns". Blood Cells Mol. Dis. 37 (1): 40–5. doi:10.1016/j.bcmd.2006.04.003. PMID 16735131.

Template:WH Template:WS